APRETUDE 200 MG / ML
APRETUDE · DIN 02547473 · VIIV HEALTHCARE ULC
Health Canada status: MARKETED
What is APRETUDE?
APRETUDE 200 MG / ML contains APRETUDE. It is listed in the Health Canada Drug Product Database under DIN 02547473, held by VIIV HEALTHCARE ULC. Health Canada currently lists it as marketed, status dated 19-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APRETUDE used for?
Pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents (≥12 years, ≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02547473 |
|---|---|
| Brand name | APRETUDE |
| Manufacturer | VIIV HEALTHCARE ULC |
| Strength | 200 MG / ML |
| Schedule | PRESCRIPTION |
| Health Canada status | MARKETED |
| Status date | 19-Jun-2024 |
How is it administered?
Oral lead-in: 30 mg daily for ~1 month. Injection: 600 mg IM at Month 1, Month 2, then every 2 months. May be initiated without oral lead-in. Must be administered by a healthcare professional.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned but content not provided), though typically room temperature for such products.
How is it supplied?
Tablets: HDPE bottles of 30. Injection: Kit containing one 3 mL single-dose vial (600 mg), syringe, adaptor, and 23-gauge needle.
Contraindications
Hypersensitivity to cabotegravir; unknown or positive HIV-1 status; concomitant use with strong inducers of UGT1A1 or UGT1A9 (e.g., carbamazepine, phenytoin, rifampin).
Warnings and precautions
Risk of drug resistance if used in undiagnosed HIV-1; must confirm negative HIV-1 status before and during use. Potential for hepatotoxicity and hypersensitivity reactions.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.